[go: up one dir, main page]

CA2393730A1 - Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i - Google Patents

Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i Download PDF

Info

Publication number
CA2393730A1
CA2393730A1 CA002393730A CA2393730A CA2393730A1 CA 2393730 A1 CA2393730 A1 CA 2393730A1 CA 002393730 A CA002393730 A CA 002393730A CA 2393730 A CA2393730 A CA 2393730A CA 2393730 A1 CA2393730 A1 CA 2393730A1
Authority
CA
Canada
Prior art keywords
seq
peptide
epitope
hla
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393730A
Other languages
English (en)
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Esteban Celis
Elissa Keogh
Robert Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,608 external-priority patent/US6602510B1/en
Application filed by Individual filed Critical Individual
Publication of CA2393730A1 publication Critical patent/CA2393730A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions ou compositions de vaccins comprenant au moins un peptide possédant moins de 600 d'acides aminés contigus présentant une identité de 100 % par rapport à une séquence native de CEA, HER 2/neu, MAGE2, MAGE3, ou p53, ce peptide possédant, de plus, au moins un déterminant antigénique sélectionné dans la table T6.
CA002393730A 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i Abandoned CA2393730A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17044899P 1999-12-13 1999-12-13
US60/170,448 1999-12-13
US09/543,608 2000-04-05
US09/543,608 US6602510B1 (en) 2000-04-05 2000-04-05 HLA class I A2 tumor associated antigen peptides and vaccine compositions
US58320000A 2000-05-30 2000-05-30
US09/583,200 2000-05-30
PCT/US2000/034318 WO2001041741A1 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Publications (1)

Publication Number Publication Date
CA2393730A1 true CA2393730A1 (fr) 2001-06-14

Family

ID=27389823

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393730A Abandoned CA2393730A1 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Country Status (5)

Country Link
EP (1) EP1242049A4 (fr)
JP (1) JP2003516344A (fr)
AU (1) AU2273701A (fr)
CA (1) CA2393730A1 (fr)
WO (1) WO2001041741A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1619207A3 (fr) * 2000-09-01 2006-02-08 Epimmune Inc. Peptides de fixation de HLA-A2.1 et leurs utilisations
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
EP1903056A3 (fr) * 2002-12-10 2008-05-07 Idm Pharma, Inc. Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
MXPA05006113A (es) * 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
DK1620456T3 (da) 2003-04-18 2014-04-22 Biotech Synergy Inc Hla-a2 tumor-associerede antigen-peptider og præparater
WO2005043155A1 (fr) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center Systeme et methode pour le traitement du cancer, notamment des cancers du systeme nerveux central
CA2700573C (fr) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
US8097256B2 (en) 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20100310640A1 (en) * 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
DK2328923T3 (en) 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
EP2391635B1 (fr) * 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
JP5661735B2 (ja) * 2009-04-01 2015-01-28 ユニバーシティ オブ マイアミ ワクチン組成物及びその使用方法
DK2427485T3 (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd CD133 epitopes
KR20140100422A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 백신 조성물
CN103961698A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CA2901984A1 (fr) * 2013-03-08 2014-09-12 Taiho Pharmaceutical Co., Ltd. Nouveau peptide portant 5 epitopes de ctl lies
EP3028048B1 (fr) 2013-07-31 2018-09-26 BioVentures, LLC Compositions permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur
HUE050164T2 (hu) 2013-10-21 2020-12-28 Taiho Pharmaceutical Co Ltd Új négy-CTL epitóp-kapcsolt peptid
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
AU2018258049B2 (en) 2017-04-26 2025-03-27 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
WO2019191494A1 (fr) 2018-03-28 2019-10-03 Epicentrx, Inc. Vaccins anticancéreux personnalisés
TWI805792B (zh) 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
AU6140998A (en) * 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Also Published As

Publication number Publication date
WO2001041741A9 (fr) 2002-05-30
WO2001041741A1 (fr) 2001-06-14
EP1242049A1 (fr) 2002-09-25
AU2273701A (en) 2001-06-18
EP1242049A4 (fr) 2005-01-05
JP2003516344A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
US6602510B1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20080279924A1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2393730A1 (fr) Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i
EP2089423B1 (fr) Vaccins à multiples épitopes spécifiques à un antigène
US9913884B2 (en) HLA-A2 tumor associated antigen peptides and compositions
JP4776131B2 (ja) ヘテロクリティックアナログおよび関連方法
US20060094649A1 (en) Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
US20160022791A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer
JP2003530083A (ja) ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
US20030224036A1 (en) Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20060018915A1 (en) Heteroclitic analogs and related methods
US9475841B2 (en) Melanoma antigen peptide and uses thereof
US9573975B2 (en) Melanoma antigen peptide and uses thereof
US20140147490A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
EP1903056A2 (fr) Peptides d'antigènes HLA-A1, -A2 -A3, -A24, -B7 et -B44 associés aux tumeurs et compositions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued